Best available Treatment (BAT)

DRUG2 trials

Sponsors

Mats Remberger, Incyte Corporation

Conditions

Chronic Graft-versus-host-diseaseGVHD, Acute

Phase 2

Decidua Stroma Cells for Steroid Resistent Acute Graft-versus-host Disease After Allo-HSCT

RecruitingNCT04118556

Mats RembergerGVHD, Acute

Start: 2021-12-01End: 2031-12-31Target: 50Updated: 2024-12-12

A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)

RecruitingNCT07124078

Incyte CorporationChronic Graft-versus-host-disease

Start: 2026-03-31End: 2029-07-31Target: 60Updated: 2026-03-20